Efficacy of Amlodipine in Pediatric Bone Marrow Transplant Patients

Abstract

The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5 ±2.1 mmHg and 117.2 ±2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5 +1.8 mmHg and 75.5 ±2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension.